Menu

Pioneering Heart Transplant Program Suspended

The move by Baylor St. Luke’s Medical Center follows an investigative news report detailing surgical errors and poor research practices.

Jun 4, 2018
Kerry Grens

ISTOCK, BARANOZDEMIRBaylor St. Luke’s Medical Center in Houston, a leading heart transplant center, has suspended its transplant program for two weeks, ProPublica and The Houston Chronicle reported jointly on Friday (June 1). The pause in operations comes within weeks of a damning investigative report by the two news outlets revealing extensive troubles with patient outcomes and research misconduct.

“I’m glad they are doing something,” Jennifer Lewis, whose husband died after a heart transplant and numerous follow-up surgeries at St. Luke’s, tells ProPublica and The Houston Chronicle. “That was my hope in speaking out and telling Lee’s story.”

In the case of Lewis’s husband, a mechanical failure in the operating room left the surgeon needing to hand-pump the patient’s newly transplanted heart for 10 minutes. A back-up defibrillator to jump-start the heart was not placed nearby, according to the surgeon, likely causing damage to the organ. The situation serves as an example of the transplant surgery performance at St. Luke’s in recent years: once a pioneering facility when transplants were first becoming available in the 1960s, it now ranks near the bottom in patient outcomes. “[T]wice as many St. Luke’s patients died within a year as would have been expected, taking into account patient characteristics and illnesses,” the news outlets state.

“Although extensive reviews are conducted on each unsuccessful transplant, the recent patient outcomes deserve an in-depth review before we move forward with the program,” Doug Lawson, CEO of the organization that owns St. Luke’s, says in a statement, according to ProPublica and The Houston Chronicle. “Our prayers are with the families, as well as all those on the waiting list.”

The journalists’ investigation also unearthed reports of research malpractice by one of the world’s leading developers of artificial hearts, Bud Frazier. A decade ago, St. Luke’s found that Frazier was implanting experimental devices into patients who didn’t qualify medically. The hospital had to repay millions of dollars of research funds to the U.S. government; none of this had been previously disclosed to the public.

Frazier is also accused of not disclosing conflicts of interest and failing to report problems with experimental heart pumps. “In the old days of medicine . . . that’s the way these guys did things,” Frank Smart, who worked with Frazier at Texas Heart, an affiliate of St. Luke’s, and who is now the chief of cardiology at Louisiana State University School of Medicine, tells ProPublica and The Houston Chronicle. “It was, ‘Well, I have an idea, and I’m the one that knows best, and by golly, I’m going to do it.’ And did that advance the field? Maybe. Is it the right thing to do? Absolutely not.”

See “If It Ain’t Broke . . .

September 2018

The Muscle Issue

The dynamic tissue reveals its secrets

Marketplace

Sponsored Product Updates

StemExpress LeukopakâNow Available in Frozen Format

StemExpress LeukopakâNow Available in Frozen Format

StemExpress, a Folsom, California based leading supplier of human biospecimens, announces the release of frozen Peripheral Blood Leukopaks. Leukopaks provide an enriched source of peripheral blood mononuclear cells (PBMCs) with low granulocyte and red blood cells that can be used in a variety of downstream cell-based applications.

New Antifade Mounting Media from Vector Laboratories Enhances Immunofluorescence Applications

New Antifade Mounting Media from Vector Laboratories Enhances Immunofluorescence Applications

Vector Laboratories, a leader in the development and manufacture of labeling and detection reagents for biomedical research, introduces VECTASHIELD® Vibrance™ – antifade mounting media that delivers significant improvements to the immunofluorescence workflow.

Best Practices for Sample Preparation and Lipid Extraction from Various Samples

Best Practices for Sample Preparation and Lipid Extraction from Various Samples

Download this white paper from Bertin Technologies to learn how to extract and analyze lipid samples from various models!

Bio-Rad Launches CHT Ceramic Hydroxyapatite XT Media and Nuvia HP-Q Resin for Process Protein Purification

Bio-Rad Launches CHT Ceramic Hydroxyapatite XT Media and Nuvia HP-Q Resin for Process Protein Purification

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced the launch of two new chromatography media for process protein purification: CHT Ceramic Hydroxyapatite XT Media and Nuvia HP-Q Resin.